Our study did not support the encouraging outcomes achieved by Sharma et al. According to Sharma et al., patients who received the LB CD2 had a significantly reduced rate of grade 3 and 4 OM development than those who received the placebo (52 per cent against 77 per cent, p < 0.001) [26]. This evidence concerns the gene CD2 and ocular melanoma.